Treatment-Resistant Depression. Part A /

Major depressive disorder (MDD) is a common but deteriorating illness worldwide with high comorbidity. The World Health Organization has estimated that MDD would be the leading cause of human disability by 2030. However, many patients with depression fail to respond to antidepressant treatment. Such...

Descripción completa

Detalles Bibliográficos
Clasificación:Libro Electrónico
Autor principal: Li, Cheng-Ta
Otros Autores: Cheng, Chih-Ming
Formato: Electrónico eBook
Idioma:Inglés
Publicado: Amsterdam, Netherlands ; Oxford, United Kingdom ; Cambridge MA : Elsevier, 2023.
Edición:First edition.
Colección:Progress in brain research ; v. 278.
Temas:
Depression, Mental > Treatment.
Acceso en línea:Texto completo
Tabla de Contenidos:
  • Intro
  • Treatment-Resistant Depression Part A
  • Copyright
  • Contributors
  • Contents
  • Preface
  • Chapter 1: Overview of treatment-resistant depression
  • Abstract
  • Keywords
  • 1. Rationale for defining treatment-resistant depression and solving unsolved problems
  • 2. Definition of an adequate antidepressant trial and TRD
  • 2.1. What is a failed response to an adequate antidepressant trial?
  • 2.2. One or two failed adequate antidepressant trials for TRD
  • 3. Epidemiology and poor outcomes of TRD
  • 3.1. Epidemiology of TRD, with a special focus on adult patients
  • 3.2. Poorer clinical outcomes and higher burden associated with TRD
  • 4. Different staging models for TRD
  • 5. Treatment strategies for adult patients with TRD
  • 5.1. Evidence-based treatment guidelines for TRD
  • 5.2. Switching and augmentation or combination
  • 5.3. Psychotherapeutic interventions
  • 5.4. Neurostimulation, glutamatergic compounds, and other experimental agents
  • References
  • Chapter 2: Genetics of antidepressant response and treatment-resistant depression
  • Abstract
  • Keywords
  • 1. Introduction
  • 2. Candidate gene association studies
  • 2.1. Glutamatergic pathway
  • 2.2. Serotonergic neurotransmission
  • 2.3. Hypothalamic-pituitary-adrenal axis
  • 2.4. Cytochrome P450
  • 2.5. Other candidate gene association studies
  • 2.6. Examining gene-gene and gene-environment interactions in antidepressant response
  • 3. Genome-wide association studies
  • 3.1. Polygenic risk score
  • 4. Whole genome sequencing
  • 5. Other genetic variations
  • 6. Epigenetics
  • 7. Discussion
  • References
  • Chapter 3: Neuroinflammation through the vagus nerve-dependent gut-microbiota-brain axis in tre
  • Abstract
  • Keywords
  • 1. Introduction
  • 2. The gut-microbiota-brain axis in depression and fecal microbiota transplantation
  • 2.1. Gut-microbiota-brain axis in depression.
  • Chapter 5: Functional MRI markers for treatment-resistant depression: Insights and challenges
  • Abstract
  • Keywords
  • 1. Introduction
  • 2. Functional magnetic resonance imaging and TRD
  • 3. Brain connectivity and activity in TRD
  • 3.1. Evidence from rs-fMRI studies
  • 3.2. Evidence from task-based fMRI
  • 3.3. TRD compared to major depressive disorder (MDD)
  • 3.4. TRD brain connectivity and activity in response to interventions
  • 3.5. Ketamine-Evidence from rs-fMRI studies
  • 3.6. Ketamine-Evidence from task-based fMRI studies
  • 3.7. Psilocybin-Evidence from fMRI studies
  • 3.8. Other non-pharmacological interventions
  • 4. Structural MRI changes in TRD
  • 4.1. Brain volume and grey matter integrity in TRD
  • 4.2. White matter integrity in TRD
  • 4.3. The relationship between structural changes, TRD symptoms, illness duration, and treatment interventions
  • 5. MRS and TRD
  • 5.1. Neurotransmitter levels in TRD at baseline
  • 5.2. Non-pharmacological interventions
  • 5.3. Pharmacological interventions
  • 6. Insights, challenges, and future steps
  • Conflict of interest
  • Funding
  • Acknowledgments
  • References
  • Chapter 6: Next generation antidepressants with novel mechanisms for treatment resistant depression
  • Abstract
  • Keywords
  • 1. Traditional antidepressants in major depressive disorder treatment and their limitations
  • 2. Consciousness, neuroplasticity, depression, and antidepressants (Fig. 1)
  • 3. Consciousness and monoamine neurotransmitters (Fig. 1)
  • 4. Altered consciousness and rapid-acting antidepressant effect: Based on the evidence of ketamine and psilocybin
  • 5. Molecular and neuroimaging mechanisms of the antidepressant effect of ketamine and psilocybin (Fig. 2)
  • 6. Ongoing clinical trials of rapid-acting antidepressant drug candidates
  • 7. Conclusion
  • References.
  • Chapter 7: Psychological aspects and psychotherapy for TRD
  • Abstract
  • Keywords
  • 1. Psychological aspects for treatment-resistant depression
  • 2. Psychotherapy for TRD
  • 2.1. Cognitive-behavioral therapy
  • 2.2. Interpersonal therapy
  • 2.3. Psychodynamic therapy
  • 2.4. Mindfulness-based cognitive therapy
  • 2.5. Acceptance and commitment therapy
  • 2.6. Dialectical behavior therapy
  • 2.7. Psychotherapeutic difficulties in treating TRD
  • 3. Conclusion
  • References.

Ejemplares similares